the relevance of the metabolites MT1 (N-tert-butyl-6-chloro-1,3,5-triazine-2,4-diamine), MT 13 (4-(tert-butylamino)-6-(ethylamino)-1,3,5-triazin-2-ol or 6-hydroxy-N2-ethyl-N4-tert-butyl-1,3,5-triazine-2,4-diamine), MT14 (4-amino-6-(tert-butylamino)-1,3,5-triazin-2-ol or N-tert-butyl-6-hydroxy-1,3,5-triazine-2,4-diamine), and of the unidentified metabolites LM1, LM2, LM3, LM4, LM5 and LM6 with respect to cancer, if terbuthylazine is classified under Regulation (EC) No 1272/2008 as ‘suspected of causing cancer’.
la pertinence des métabolites MT1 (N-tert-butyl-6-chloro-1,3,5-triazine-2,4-diamine), MT13 (4-(tert-butylamino)-6-(éthylamino)-1,3,5-triazine-2-ol ou 6-hydroxy -N2-éthyl-N4- tert-butyl-1,3,5-triazine-2,4-diamine), MT14 (4-amino-6-(tert-butylamino)-1,3,5-triazine-2-ol ou N-tert-butyl-6-hydroxy-1,3,5-triazine-2,4-diamine), et des métabolites non identifiés LM1, LM2, LM3, LM4, LM5 et LM6 par rapport au cancer, si la terbuthylazine est classée en tant que substance «susceptible de provoquer le cancer» conformément au règlement (CE) no 1272/2008.
